Latest Pharmaceuticals News

Cann Group Limited has finalized a $15.3 million settlement with National Australia Bank, releasing all security and closing loan facilities as part of a broader debt restructuring. The company is advancing a $9 million new loan and a $9 million capital raise, including a share purchase plan closing November 17.

Mayne Pharma has received notice of Cosette Pharmaceuticals' intention to appeal a court ruling in their acquisition dispute, potentially delaying the proposed takeover. The legal saga continues as key approvals and hearings loom.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.

Epsilon Healthcare has commenced operations of its new pharmacy division and extended a key loan facility, signaling a strategic pivot towards integrated healthcare and financial stability after recent restructuring.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.

Neuren Pharmaceuticals reported a milestone quarter with DAYBUE net sales reaching US$101.1 million, driving a 24% jump in royalty income. The expanding patient base and community physician uptake signal strong growth ahead.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Mayne Pharma updates shareholders on the extended Foreign Investment Review Board approval deadline and the rescheduled court hearing for its acquisition scheme by Cosette Australia BidCo.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.